Article info

Download PDFPDF

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Authors

  1. Correspondence to Dr Josef S Smolen, Medical University of Vienna, Vienna, Austria; josef.smolen{at}meduniwien.ac.at
View Full Text

Citation

Smolen JS, Mease P, Tahir H, et al
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Publication history

  • Received March 19, 2020
  • Revised June 5, 2020
  • Accepted June 9, 2020
  • First published July 13, 2020.
Online issue publication 
September 14, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.